Editing Clinical Trials (section)

=== Memorial Sloan Kettering Intrapleural CAR-T Program (NCT04577326) ===

This groundbreaking program pioneered regional delivery of CAR-T cells directly into the pleural space, minimizing systemic toxicity while maximizing tumor contact.<ref>[https://dandell.com/mesothelioma-lawyer/new-york/ New York Mesothelioma Lawyers], Danziger & De Llano</ref>

{| style="width:100%; background:#d4edda; border:1px solid #28a745; border-left:5px solid #28a745; border-radius:4px; margin:1em 0;"
|-
| style="padding:15px; color:#155724;" | '''✓ Breakthrough Results:''' Memorial Sloan Kettering's intrapleural CAR-T program achieved '''83% one-year survival''' for malignant pleural mesothelioma patients—dramatically exceeding historical outcomes of 12-16 months median survival with standard therapy.
|}

'''Published Results:'''
* '''One-year survival:''' 83% for malignant pleural mesothelioma patients
* '''CAR-T persistence:''' Cells detected in peripheral blood for more than 100 days in 39% of patients
* '''Durable responses:''' One patient achieved partial response lasting 26 months
* '''Safety profile:''' Intrapleural administration was safe and well tolerated
* '''Combination approach:''' 18 patients received CAR-T with pembrolizumab, demonstrating enhanced function